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Abstract
NK cells are pivotal sentinels of the innate immune system and distinct subpopulations in peripheral blood have been
described. A number of studies addressed HIV-induced alterations of NK cell phenotype and functionality mainly focusing
on CD56
dimCD16
+ and CD56
2CD16
+ NK cells. However, the impact of HIV-infection on CD56
bright NK cells is less well
understood. Here we report a rise of CD56
bright NK cells in HIV-infected individuals, which lack CCR7-expression and strongly
correlate with HIV viral load. CCR7
2CD56
bright NK cells were characterized by increased cytolytic potential, higher activation
states and a more differentiated phenotype. These cells thus acquired a number of features of CD56
dimCD16
+ NK cells.
Furthermore, CD56
bright NK cells from HIV patients exhibited higher degranulation levels compared to uninfected
individuals. Thus, chronic HIV-infection is associated with a phenotypic and functional shift of CD56
bright NK cells, which
provides a novel aspect of HIV-associated pathogenesis within the NK cell compartment.
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Introduction
NK cells are effector cells of the innate immune system, which
can spontaneously sense and lyse virus-infected cells [1,2]. Distinct
NK cell subpopulations have been described. The majority of
human NK cells in peripheral blood are CD56
dimCD16
+ cells
whereas CD56
bright cells only constitute approximately 10% of the
blood NK cell pool [3]. Among other markers, CD56
bright NK
cells are characterized by high expression of type II membrane
glycoprotein CD94, L-selectin CD62L and lymph-node homing
receptor CCR7 [4,5] but low expression of the low affinity IgG-Fc-
receptor III (CD16), killer cell immunoglobulin-like receptors
(KIRs) and cytolytic molecules such as perforin and granzyme B,
which are predominantly features of CD56
dimCD16
+NK cells [1].
Thus, NK cell subsets seem to have distinct roles in the immune
response. Generally, CD56
dimCD16
+ NK cells are viewed as the
cytotoxic NK cell subpopulation whereas CD56
bright NK cells
were described to have regulatory functions by means of cytokine
production, such as IFN-c and TNF among others [1,3].
Recent studies have emphasized the pivotal contributions of NK
cells in the host defense against HIV [6,7]. However, a number of
defects in NK cell biology caused by HIV-infection have been
documented [8]. We have shown an association of chronic HIV-
infection with a significant decline of less differentiated and
functionally more active CD56
dimCD16
+ NK cells, which are
either CD57
2 or CD57
dim [9]. In addition, we and others
characterized an expansion of CD56
2CD16
+ NK cells in HIV
infection with a terminally differentiated phenotype [10–12],
which might reflect an increased turnover of NK cells in chronic
HIV infection [13]. Nonetheless, little is known about the impact
of HIV viremia and chronic HIV-1 infection on CD56
bright NK
cells.
CD56
bright NK cells have been suggested to be less differenti-
ated NK cells, which can give rise to CD56
dimCD16
+ NK cells
[14] and an accumulating body of evidence seems to corroborate
this view [5,9,15–19]. Enhanced cytolytic activity of these cells has
been previously associated with HIV-infection [11,20]. Here we
show that high HIV-1 viral load significantly correlates with a loss
of CD56
bright NK cells expressing CCR7. CCR7
2CD56
bright NK
cells exhibited a number of features resembling CD56
dimCD16
+
NK cells. These results thus present evidence for profound
alterations of CD56
bright NK cells in HIV-infection.
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Ethical Approval
The study was performed in strict accordance with the ethical
principles as outlined in the WMA Declaration of Helsinki. All
study subjects gave written, informed consent prior to their
participation. The protocol was approved by the local ethics
committee (Votum der Ethikkommission der MHH No. 3150).
Study Subjects
We obtained peripheral blood samples from 37 untreated and
15 treated HIV-seropositive subjects on highly active antiretroviral
therapy (HAART) and 16 uninfected individuals in the HIV
outpatient clinic of the Medizinische Hochschule Hannover
(MHH). A summary of the demographical data of the studied
groups is shown in Table 1 and more detailed information on the
HIV-seropositive blood donors are provided in Table S1. Plasma
HIV-1 RNA levels were determined using the VERSANT-HIV-
1 RNA Assay, version 3.0 (bDNA, Bayer Diagnostics, Berkeley,
CA) and absolute lymphocyte counts were routinely determined
by differential hemograms. Frequencies of CD4
+ T cells and other
lymphocyte subpopulations were determined by flow cytometry
using a cocktail of diagnostic staining antibodies from Beckman
Coulter either directed against CD45, CD3, CD4 and CD8 or
CD45, CD56, CD19, CD3 and CD16. Absolute CD4
+ T cell
counts were calculated by determining their frequency of the total
lymphocytes.
Isolation of Mononuclear Cells
PBMCs were isolated from fresh blood as described previously
[12,21]. Aliquots of 10
7 PBMCs each were cryopreserved in heat-
inactivated FCS supplemented with 10% dimethyl sulfoxide
(DMSO) (Merck).
Phenotypic Analysis of NK Cells by Flow Cytometry
A list of monoclonal antibodies employed in this study is
available upon request. Staining and flow cytometric analysis was
performed as described before [9]. To define absolute numbers of
NK cell subpopulations, we first determined the percentages of
these subsets of total lymphocytes and then determined their
absolute numbers using the absolute counts of lymphocytes.
Intracellular expression of perforin, granzyme B and Ki-67 was
analyzed in unstimulated NK cells using ‘Fix and Perm’ kit
(Invitrogen) according to the instructions provided by the
manufacturer. CD56
bright NK cells were only analyzed if at least
1,000 gated events were acquired.
CD107a Degranulation Assay and Intracellular Cytokine
Staining
Functional NK cell assays were performed as described
previously [9]. Briefly, sorted NK cells or PBMCs were stimulated
with 100 ng/ml IL-12, 10 ng/ml IL-15 and/or K562 cells at an
E:T ratio of 2:1 or 100,000 K562 cells per 1 million PBMCs.
CD107a degranulation after 6 hours of stimulation and incubation
was detected as described before [9,22]. Anti-IFN-c Pacific-Blue
(clone 4S.B3, Biolegend) and anti-TNF Alexa Fluor 700 (clone
MAb11, BD Biosciences) were used to detect intracellular
expression of cytokines.
NK Cell Differentiation Assay
CCR7
+CD56
bright NK cells were sorted and suspended in
RPMI 1640 supplemented with 10% FCS (Biochrom), 100 U/ml
penicillin and 100 mg/ml streptomycin, 2 mmol/l L-glutamine
and 1 mmol/l sodium pyruvate. The purity of sorted cells
exceeded 95%. CCR7
+CD56
bright NK cells were cultured at a cell
density of 100,000 cells per well in the presence or absence of
100 U/ml IL-2, 25 ng/ml IL-12 and 25 ng/ml IL-15. At days 0, 3
and 5 phenotypic analyses were performed by flow cytometry.
Statistical Analysis
GraphPad Prism (version 5.0) software was used for statistical
evaluation of data. Pearson analysis was employed to determine
correlations. Unpaired, two-tailed t test when comparing two
groups or One-way ANOVA followed by Tukey test when
comparing more than two groups were performed and P values of
less than 0.05 were considered significant.
Results
We excluded T cells, B cells and monocytes from the analysis as
previously described [9] and identified CD56
bright NK cells as
shown in Fig. 1A. This gating strategy included CD16
+ expressing
CD56
bright NK cells, which were still distinguishable from
CD56
dimCD16
+ NK cells due to their bright CD56 expression.
We first assessed the expression of CCR7, CD62L, CXCR3 and
CD16 on CD56
bright NK cells in HIV-seronegative donors as well
as in a cohort of HIV-patients, which included treated and
untreated subjects. There was a substantial decrease of CCR7
+
and CXCR3
+ and increase of CD16
+ CD56
bright NK cells in
untreated HIV-seropositive blood donors compared to healthy
controls (Fig. 1B). These alterations were partially reversed in
patients on HAART with suppressed viral loads for more than one
year although the decrease of frequencies of CD16
+CD56
bright NK
cells in treated subjects compared to untreated patients did not
reach statistical significance. Notably, the relative loss of
CXCR3
+CD56
bright cells was not reversed in HIV-infected
patients after treatment. Analysis of HIV-patients, which had
been treated for less than one year, still exhibited loss of CCR7-
expressing CD56
bright NK cells despite suppression of viral load
below detection limits (data not shown). This suggests that
reversing the impact of HIV-infection on CD56
bright NK cell
phenotype requires time.
Table 1. Summary of demographical data of study participants.
Number of
subjects Group
Male/Female
ratio
Mean age 6
SD
Mean CD4 T cell count
(n/ml) 6 SD
Median Viral
load (n/ml)
Mean CD4/CD8 T cell
ratio 6 SD
15 HIV
+, ART 2.75 44611 4806212 undetectable 0.6660.28
38 HIV
+, Untreated 2.08 41614 4676271 11450 0.4860.31
16 Control 1.67 38613 8486191 seronegative 1.6760.52
The profiles of all study participants are shown in a summary.
doi:10.1371/journal.pone.0044820.t001
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CD62L are frequently co-expressed on T cells [23]. Furthermore,
the presence of CD62L on NK cells has been associated with
a polyfunctional cell profile and CD62L is highly expressed on
CD56
bright NK cells [24]. Notably, and in contrast to our
observations of decreased frequencies of CCR7
+CD56
bright NK
cells, no significant alterations were found in terms of numbers of
CD62L-expressing CD56
bright NK cells in HIV-infection (Fig. 1B).
There was no correlation between the rise of CCR7
2CD56
bright
NK cells and percentages of CD16-expressing cells and only
a modest correlation between frequencies of CCR7 and CD62L
expressing CD56
bright NK cells (Fig. 1C). We also assessed possible
relationships between the decreased percentages of
CXCR3
+CD56
bright NK cells with either percentages of
CCR7
+CD56
bright or CD16
+CD56
bright NK cells but were unable
to find significant correlations (Figure S1A) and the percentages of
Figure 1. Loss of CCR7-expressing CD56
bright NK cells correlates with clinical disease markers. (A) Representative flow cytometry plots
defining CD56
bright NK cells. Numbers indicate percentage of the gated population. (B) Representative CCR7, CD62L, CXCR3 and CD16 expression
data and summary data all gated on CD56
bright NK cells. Horizontal bars in dot plot indicate mean values. (C) Pearson’s correlation analysis between
frequencies of either CD62L
+ or CD16
+CD56bright NK cells and CCR7
+CD56
bright NK cells in untreated HIV-seropositive patients. (D) Pearson’s
correlation analysis between frequencies of CCR7
+, CD62L
+, CXCR3
+ or CD16
+ cells of total CD56
bright NK cells with either viral load or CD4
+ T cell
counts in untreated HIV-positive subjects. *, P,0.05; ***, P,0.001; NS – not significant.
doi:10.1371/journal.pone.0044820.g001
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+ cells did not vary in CCR7
+ compared to
CCR7
2CD56
bright NK cells (Figure S1B).
Our cohort of untreated HIV-infected patients comprised elite
viral controllers as well as non-controllers with rapid disease
progression. This prompted us to analyze whether HIV viral loads
were associated with the observed decrease of CCR7-expressing
CD56
bright NK cells. Indeed, we found highly significant inverse
correlation between frequencies of CCR7
+CD56
bright NK cells
and HIV-RNA copies/ml in these untreated patients (Fig. 1D). In
addition, there was a weaker yet significant correlation between
percentages of CCR7
+CD56
bright or CXCR3
+CD56
bright NK cells
with CD4
+ T cell counts (Fig. 1D). No correlations with viral copy
numbers and CD4
+ T cell counts were found for CD16- or
CD62L-expressing CD56
bright NK cells. We thus demonstrate
a direct correlation of loss of CCR7-expressing but not CD16- or
CD62L-expressing CD56
bright NK cells with these clinical disease
parameters.
The absolute numbers of CD56
bright NK cells in untreated
HIV-infected patients compared to healthy controls were not
substantially decreased (Fig. 2A). However, the relative loss of
CCR7-expressing CD56
bright NK cells was also reflected in their
absolute cell numbers and we also detected increased absolute
counts of CCR7
2CD56
bright NK cells in untreated HIV-seropos-
itive subjects (Fig. 2B).
We next tested the hypothesis whether the relative and absolute
decrease of CCR7
+C56
bright NK cells in chronic HIV-infection
was due to their increased susceptibility of apoptosis. To address
this question we measured expression of Fas (CD95) on NK cell
subsets in freshly isolated PBMC samples. There were no
statistically significant differences when comparing
CCR7
-CD56
bright, CCR7
+CD56
bright and CD56
dimCD16
+ NK
cells using a One-Way ANOVA followed by a Tukey post-test
(Fig. 2C). However, when we tested the hypothesis whether
CCR7
-CD56
bright and CCR7
+CD56
bright NK cells differed in the
percentages of CD95-expressing cells, we found higher frequencies
among CCR7
-CD56
bright NK cells (P,0.016, t test). Highest
frequencies were found on CD56
dimCD16
+ NK cells (Fig. 2C).
The frequency of CD95-expressing CCR7
+CD56
bright NK cells
was slightly elevated in untreated HIV-infected patients compared
to uninfected control subjects. (Figure S2A) and we observed
a non-significant negative association between percentages of
CD95
+ and CCR7
+CD56
bright NK cells (Figure S2B). We also
studied the frequencies of CD56
bright NK cells expressing the TNF
receptor type II (CD120b) and found that CD56
bright NK cells
from untreated HIV-positive subjects exhibited higher percentages
of CD120
+ cells (Figure S2C). Nonetheless, frequencies of
CD120b
+ cells ranged at relatively low levels with an average
percentage of lower than 10%. Unlike CD95, relative numbers of
CD120
+ cells did not vary significantly in CCR7
+ compared to
CCR7
2CD56
bright cells (Figure S2D). Highest frequencies of
CD120
+ cells were found within the CD56
dimCD16
+ NK cell
subpopulation. In addition, there was no detectable expression of
TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) on
NK cells in freshly isolated PBMCs from HIV-patients (data not
Figure 2. Relative and absolute loss of CCR7
+CD56
bright NK cells is not attributable to apoptosis. (A) Absolute cell numbers of CD56
bright
NK cells are depicted. Horizontal bars indicate means. (B) Absolute cell numbers of either CCR7
+ or CCR7
2CD56
bright NK cells are shown. (C)
Representative flow cytometry data of CD95 on gated CD56
bright NK cells and respective summary data derived from untreated HIV-patients.
Numbers in flow cytometry plots indicate frequencies of quadrants and horizontal bars in dot plot indicate mean values. (D) Pearson’s correlation
analysis between frequencies of CCR7- and CD69-expressing CD56
bright NK cells. *, P,0.05; ***, P,0.001; NS – not significant.
doi:10.1371/journal.pone.0044820.g002
CD56
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to TRAIL-mediated apoptosis [25]. We found no significant
intracellular expression of Caspase-3 or Bcl-2 in CCR7
2 and
CCR7
+CD56
bright NK cells ex vivo (data not shown) indicating low
or undetectable apoptosis levels within the CD56
bright NK cell
subset in freshly isolated PBMCs.
Cytokine-induced activation of NK cells can lead to down-
regulation of CCR7 after several days [17]. Thus, a plausible
explanation for decreased numbers of CCR7
+CD56
bright NK cells
despite stable numbers of total CD56
bright NK cells could be an
overall activated state of the immune system in HIV-seropositive
subjects. Indeed, we detected a moderate yet significant negative
correlation between frequencies of CD56
bright NK cells expressing
the activation marker CD69 and CCR7
+CD56
bright NK cells
(Fig. 2D). This suggests that immune activation is a correlate for
the alterations of the CD56
bright NK cells subset.
We next sought to answer the question whether loss of CCR7
on CD56
bright NK cells was associated with an altered phenotype.
We identified a decrease of CD62L-, NKG2A- and CD27-
expressing cells among CCR7
2CD56
bright NK cells compared to
CCR7
+CD56
bright NK cells in untreated HIV-seropositive indi-
viduals (Fig. 3). A further decrease of percentages of CD62L
+,
NKG2A
+ and CD27
+ cells could be seen among
CD56
dimCD16
+NK cells compared to CCR7
+CD56
bright NK
cells or compared to CCR7
2CD56
bright NK cells (Fig. 3).
NK cell differentiation was previously shown to be accompanied
by an increase in KIR-expressing cells [5,9,18]. The expression of
KIR3DL1 (CD158e) was highest on CD56
dimCD16
+ NK cells but
CCR7
2CD56
bright cells had an increase of KIR3DL1-expressing
cells compared to CCR7
+ cells (Fig. 3). We also found considerable
increase of cells expressing CD69 among CCR7
2CD56
bright NK
cells in comparison with their CCR7
+ counterpart, which was
again exceeded by the levels of CD56
dimCD16
+ NK cells
suggesting higher activation states in these populations (Fig. 3).
Furthermore, moderately higher percentages of CD16
+ cells were
found among CCR7
2CD56
bright NK cells. Because we were
unable to identify a correlation between frequencies of
CCR7
+CD56
bright and CD16
+CD56
bright NK cells (Fig. 1C) we
addressed the question whether frequencies of CCR7
+ cells varied
between CD16
+ and CD16
2CD56
bright NK cells.
CD16
+CD56
bright NK cells exhibited a small but statistically
significant decrease of CCR7-expressing cells (Figure S3A).
Altogether, our data indicate that HIV-associated
CCR7
2CD56
bright NK cells display an ‘intermediate’ phenotype
sharing properties of CD56
bright as well as CD56
dimCD16
+ NK
cells.
Overall, CCR7
2CD56
bright NK cells are only present at low
frequencies in uninfected individuals. We hypothesized that the
intermediate phenotype of CCR7
2CD56
bright NK cells was not
exclusively induced by chronic HIV infection but might also be
present at lower frequencies in healthy control subjects. We were
indeed able to identify a number of control individuals and HIV-
patients on HAART with moderate numbers of
CCR7
2CD56
bright NK cells. Overall, there were similar trends
in terms of phenotypic differences between CCR7
2 and
CCR7
+CD56
bright NK cells (Figure S3B, C). These findings
therefore imply that CCR7
2CD56
bright NK cells do occur at low
frequencies in HIV-seronegative subjects and HAART-treated
Figure 3. CCR7
2CD56
bright NK cells exhibit phenotypic features of CD56
dimCD16
+ cells. Representative expression data of CD62L, NKG2A,
CD27, KIR3DL1, CD69 and CD16 on gated CCR7
+ or CCR7
2 CD56
bright cells and respective summary data including CD56
dimCD16
+ NK cells, from
untreated HIV-seropositive individuals. Numbers represent percentages of gated events and horizontal bars in dot plots indicate mean values. *,
P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0044820.g003
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ones observed in CCR7
2CD56
bright cells in viremic HIV-patients.
We next addressed the question whether CCR7
2CD56
bright
NK cells display functional characteristics of CD56
dimCD16
+ NK
cells. Percentages of granzyme B as well as perforin producing cells
among CCR7
2CD56
bright NK cells were significantly augmented
in comparison with CCR7
+CD56
bright NK cells in untreated HIV-
seropositive subjects (Fig. 4A). Importantly, numbers of granzyme
B
+ and perforin
+ of CCR7
2CD56
bright NK cells were again
between the levels of the CCR7
+CD56
bright NK cell subset and
CD56
dimCD16
+ NK cells (Fig. 4A). Similar trends were observed
in uninfected subjects (Figure S3D).
We next assessed the ability of total CD56
bright NK cells to
degranulate, which was shown to be closely related to the cytotoxic
activity of NK cells [26,27]. Treatment of NK cells with IL-12 and
IL-15 only induced weak degranulation of CD56
bright NK cells
and the average percentage of CD107a-expression was 6.6% (data
not shown). We thus treated sorted NK cells with IL-12, IL-15 and
K562 cells to achieve robust activation of NK cells and to be able
to measure cytokine-production and degranulation at the same
time. Notably, there was a significant increase of CD107a-
expressing CD56
bright NK cells from untreated HIV-infected
patients compared to control subjects, which was reversed in
treated patients (Fig. 4B). Next, we addressed the question whether
higher numbers of degranulating cells could be found among
CCR7
2CD56
bright NK cells compared to CCR7
+CD56
bright cells
in untreated HIV-infected subjects. There was only a non-
significant, minor increase of CD107a-expressing cells among
CCR7
2CD56
bright NK cells (Fig. 4C). We also evaluated the
ability of CD56
bright NK cells to produce cytokines. Notably, we
found increased numbers of cells expressing IFN-c in
CCR7
2CD56
bright NK cells in medium-treated PBMCs without
further stimulation (Fig. 4D), which corroborates our hypothesis
that these cells display a more activated phenotype ex vivo. Upon
Figure 4. Functional differences between CCR7
2 and CCR7
+CD56
bright NK cells from HIV-infected donors indicate high activation
states. (A) Representative flow cytometry plots of granzyme B and perforin expression on gated CD56
bright NK cells and summary data including
CD56
dimCD16
+ cells, from untreated HIV-infected subjects. Horizontal bars in dot plots show mean values. Numbers in corners represent percentage
of quadrant. (B) Representative histograms and summary data of CD107a degranulation in CD56
bright cells from uninfected controls, untreated and
HAART-treated HIV-patients. Data was generated using sorted NK cells stimulated with IL-12, IL-15 and K452 cells. (C) Representative flow cytometry
plot of CD107a degranulation on gated CD56
bright NK cells and summary data of degranulation in CCR7
+CD56
bright, CCR7
2CD56
bright and CD56
dim NK
cells from untreated HIV-infected subjects is shown. Data was generated using whole PBMCs stimulated with IL-12, IL-15 and K562 cells. Numbers in
corners represent percentage of quadrant. (D) Spontaneous expression of IFN-c in medium-only treated NK cell subsets is shown in a representative
flow cytometry plot and a summary data graph. Data from untreated HIV-positive patients is shown and numbers in corners indicate percentages of
quadrants. (E) Representative Ki-67-expression data and summary data on gated CCR7
+ or CCR7
2 CD56
bright cells and respective summary data
including CD56
dimCD16
+ NK cells from untreated HIV-seropositive subjects. Numbers in flow cytometry histogram plots indicate percentage of gated
events. ***, P,0.001; NS – not significant.
doi:10.1371/journal.pone.0044820.g004
CD56
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CD56
bright NK cells in untreated HIV-seropositive individuals
compared to uninfected subjects as well as a non-significant
increase of TNF-expressing cells (Figure S4A).
We next sought to answer the question whether occurrence of
CCR7
2CD56
bright NK cells in untreated, chronic HIV-infection
was associated with increased in vivo proliferation. Higher
frequencies of Ki-67
+ cells were found among CD56
bright NK
cells in comparison with the CD56
dimCD16
+ subset (Fig. 4E).
However, we were not able to detect a significant difference
between CCR7
2 and CCR7
+CD56
bright NK cells (Fig. 4E). In
accordance with a previous study [13], there were higher numbers
of Ki-67
+ NK cells in untreated HIV-infected patients compared
to the uninfected control cohort in every NK cell subset we tested
(Figure S4B).
Since our data suggested that CCR7
2CD56
bright NK cells could
represent an intermediate NK cell subset in the context of
a possible differentiation pathway from CD56
bright to
CD56
dimCD16
+ NK cells, we wondered whether we could
reproduce some of our ex vivo observations in an in vitro culture
model. To test this hypothesis, we sorted CCR7
+CD56
bright NK
cells from uninfected blood donors (Figure S5A) and cultured these
cells either in the presence or absence of 100 U/ml IL-2, 25 ng/
ml IL-12 and 25 ng/ml IL-15. Culturing CCR7
+CD56
bright NK
cells in medium alone for five days was not sufficient to induce
significant loss of CCR7 expression (Figure S5B). However,
cytokine-treated CCR7
+CD56
bright NK cells gradually exhibited
an increasing loss of CCR7 by days 3 and 5 (Figure S5B).
Furthermore, treatment of cells with cytokines induced the
expression of granzyme B and perforin whereas medium alone
was not sufficient to substantially up-regulate these proteins (Figure
S5C). However, it should be emphasized that the down-regulation
of CCR7 was only modest and we did not observe a significant
downregulation of CD56. These results thus indicate that cytokine
treatment of CCR7
+CD56
bright NK cells can partially produce
a phenotype similar to the altered profile of CD56
bright NK cells in
chronic HIV-infection.
Discussion
A number of previous studies suggested that CD56
bright NK
cells are less differentiated progenitors of CD56
dimCD16
+ NK cells
[5,9,15–18]. In support of this model, intermediate subsets of NK
cells have been identified. Within the CD56
dim NK cells, a subset
of CD94
high-expressing cells was shown to have an intermediate
profile as shown by expression levels of CD62L, CD2, KIRs,
granzyme B, perforin and functional markers, which ranged
between the CD56
bright and the CD94
lowCD56
dim NK cell subset
[5]. Furthermore, a recent study proposed a CD16-expressing
subset within the CD56
bright NK cells to be an intermediate stage
of NK cell differentiation indicated by their phenotypic and
functional features [19]. However, not much is known about the
impact of chronic HIV-infection on CD56
bright NK cells or
putative alterations of intermediate NK cell populations.
Here, we provide an extensive phenotypic analysis of the
alterations of CD56
bright NK cells in chronic HIV infection. We
demonstrate that untreated HIV-infection is associated with
increased numbers of CD56
bright NK cells expressing CD16 and
a loss of CXCR3-expressing cells. We report a substantial relative
and absolute increase of CCR7
2CD56
bright NK cells and
conversely diminished numbers of CCR7
+CD56
bright NK cells in
viremic HIV-1 infection. However, whereas the percentage of
CCR7
+CD56
bright NK cells was almost restored to normal levels
after prolonged anti-retroviral treatment, absolute numbers of
CCR7
+CD56
bright cells remained at lower levels in treated
patients. We also demonstrate overall lower absolute counts of
CD56
bright NK cells in our cohort of treated HIV-patients
compared to uninfected subjects. Thus, the unrestored absolute
numbers of CCR7
+CD56
bright NK cells in the cohort of treated
HIV-patients could represent a reflection of the low absolute
CD56
bright NK cell counts.
The relative increase of CD16
+CD56
bright NK cells could
suggest an impact of HIV on a previously characterized
intermediate NK cell subpopulation [19]. However, this increase
did neither correlate with viral load or CD4
+ T cell counts, nor did
we find correlations with diminished frequencies of
CCR7
+CD56
bright NK cells. In addition, although there was
a positive correlation between relative numbers of
CXCR3
+CD56
bright NK cells and absolute T cell counts, there
was no correlation with viral load or with CCR7
+CD56
bright NK
cells. Our data therefore suggest that the loss of CCR7-expressing
CD56
bright NK cells is distinct from up-regulation of CD16 or loss
of CXCR3
+CD56
bright cells.
Furthermore, we demonstrated that the CCR7
2CD56
bright
subpopulation displays a number of similarities with
CD56
dimCD16
+ NK cells as shown by increased frequencies of
cells expressing granzyme B, perforin, KIR, CD16 and decreased
numbers of cells expressing CD62L, NKG2A and CD27. Despite
elevated cell numbers expressing granzyme B and perforin, the
CCR7
2CD56
bright NK cell subset exhibited similar levels of
degranulation compared to CCR7
+CD56
bright cells but higher
spontaneous IFN-c production. Increased cytolytic properties of
CCR7
2CD56
bright NK cells were not accompanied by signifi-
cantly enhanced proliferative activity as monitored by intracellular
Ki67 staining. Altogether, the loss of CCR7 on CD56
bright NK
cells marks a phenotypic shift of CD56
bright NK cells towards
a CD56
dimCD16
+ NK cell-like phenotype, which strongly
correlates with clinical parameters of HIV-associated immune
disease. Importantly, CCR7
2CD56
bright NK cells occur only at
relatively low frequencies in uninfected subjects and exhibit
comparable phenotypic properties to the CCR7
2CD56
bright NK
cell population in HIV-infected patients.
The loss of CCR7 could imply a loss of migratory capacity to
lymph nodes. Interestingly, a previous study in rhesus macaques
reported a loss of CCR7-expressing but not CD62L-expressing
CD56
+ NK cells after SIV-infection [28]. Similar to our data,
Reeves et al. reported an increase of granzyme B- and perforin-
expression and higher activation states in CD56
+ NK cells. In
SIV-infected macaques, the loss of CCR7 on NK cells was
accompanied by an increase of gut-homing receptor a4ß7-
expression implying trafficking of NK cells into gut mucosal
tissues [29].
Our observations could potentially be explained by an up-
regulation of CD56 on activated CD56
dimCD16
+ NK cells.
However, the scarce expression of KIRs (Fig. 3) and the absence
of CD57 as well as the high expression profiles of CD94 (data not
shown) on CCR7
-CD56
bright NK cells make this possibility less
plausible. In addition, apoptosis had been suggested to play
a critical role in the overall decrease of absolute numbers of NK
cells [13]. Our findings however indicate overall relatively low
numbers of CD95
+ and CD120b
+ cells among CD56
bright NK
cells. In addition, there was a two-fold increase of percentages of
CD95
+ cells among the expanded CCR7
-CD56
bright NK cell
subset compared to the decreased CCR7
+CD56
bright cell subset.
Thus, even though we cannot conclusively rule out a potential
contribution of apoptosis to the loss of CCR7
+CD56
bright NK cells
our results indicate that it is unlikely that apoptosis is the defining
cause for the selective depletion of the CCR7
+CD56
bright subset.
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mediated apoptosis in viremic HIV-1 patients is more frequently
found within the more differentiated CD56
dimCD16
+ NK cell
population [13].
One of the hallmarks of chronic HIV-infection is systemic
immune activation of the host [30]. The finding that CD69-
expression is substantially increased on the CCR7
-CD56
bright
population supports a dominant role for immune activation in the
observed alteration of this NK cell phenotype in chronic HIV-1
infection. Similar observations have also been described on
CD56
dimCD16
+ and CD56
negCD16
+ NK cells in HIV-1 infection
[9,12]. In support of this notion, we identified a negative
correlation between percentages of CD69-expressing CD56
bright
cells and CCR7
+CD56
bright NK cells. This finding indicates that
activation of NK cells is a correlate for the relative loss of the
CCR7
+CD56
bright NK cell subpopulation. Human NK cells
express various cytokine receptors [1] and a previous study
showed that stimulation with either IL-2 or IL-12 was enough to
induce loss of CCR7 on CD56
bright cells and acquisition of
CD56
dimCD16
+ cell resembling characteristics, such as granzyme
B expression clearly suggesting that cytokines can induce NK cell
differentiation [17]. Notably, we were able to generate similar data
when we cultured and cytokine-activated highly purified
CCR7
+CD56
bright NK cells instead of using bulk CD56
bright NK
cells. Thus, it is tempting to speculate that CCR7
+CD56
bright NK
cells could represent a less differentiated NK cell subset. However,
in our in vitro system we were unable to demonstrate a full
transformation of CCR7
+CD56
bright cells into CD56
dim NK cells,
which is in accordance with a previous study [16], suggesting the
involvement of additional factors in the process of NK cell
differentiation, such as interaction with tissue fibroblasts. Further
studies in appropriate animal models such as humanized mice or
nonhuman primates could be helpful to better define the precise
ontogeny of both, CCR7
+ and CCR7
2CD56
bright NK cells.
Importantly, the phenotypic and functional skewing of
CD56
bright NK cells, which we report in this manuscript, may
not be limited to chronic HIV-infection. A number of viruses are
able to evade a complete eradication by the host immune
surveillance to establish a chronic, life-long infection in humans
[31]. Similarly to HIV, hepatitis B virus (HBV) and hepatitis C
virus (HCV) are known to undergo continuous cycles of replication
during chronic infection, thus providing constant antigenic
stimulation of host lymphocytes, which could also induce NK cell
activation [32]. It will thus be interesting to see if and how chronic
viral infections can impact NK cell differentiation stages in
humans although it should be noted that the degree of systemic,
chronic immune activation in HIV pathogenesis seems to exceed
other known chronic viral infections in humans.
In summary, we provide a thorough characterization of the
changes within the CD56
bright NK cell subset in chronic HIV
infection, which is reflected in a shift towards CD56
dimCD16
+ NK
cells thus providing a novel aspect of HIV-associated alterations of
the NK cell compartment.
Supporting Information
Figure S1 Alterations of CXCR3 expression on
CD56
bright NK cells do not correlate with alterations of
CCR7 expression in chronic HIV infection. (A) Pearson’s
correlation analyses between frequencies of CXCR3
+CD56
bright
NK cells and CCR7
+CD56
bright or CD16
+CD56
bright NK cells in
untreated HIV-seropositive patients are shown. (B) The frequen-
cies of CXCR3
+ cells in CCR7
+, CCR7
2CD56
bright or CD56
dim
NK cells derived from untreated HIV-seropositive individuals are
shown. Horizontal bars indicate means. *, P,0.05; **, P,0.01;
***, P,0.001; NS – not significant.
(EPS)
Figure S2 CD95 and CD120b are up-regulated on NK
cell subpopulations in chronic HIV-infection. (A) Summa-
ry data of frequencies of CD95-expressing CCR7
+CD56
bright NK
cells is shown in uninfected, treated and untreated HIV-positive
individuals. (B) Pearson’s correlation analysis between frequencies
of CD95
+CD56
bright NK cells and CCR7
+CD56
bright NK cells in
treated and untreated HIV-seropositive patients. (C) Summary
data of percentages of CD120b
+CD56
bright NK cells is shown.
Horizontal bars represent means. (D) The frequencies of CD120b
+
cells in CCR7
+, CCR7
2CD56
bright or CD56
dim NK cells derived
from untreated HIV-seropositive individuals are shown. Horizon-
tal bars indicate means. ***, P,0.001.
(EPS)
Figure S3 Phenotypical differences between CCR7
2 and
CCR7
+CD56
bright NK cells observed in healthy controls
and HAART-treated HIV-1 infected patients. (A) The
frequencies of CCR7
+ cells in CD16
+ and CD16
2CD56
bright NK
cells are shown. Horizontal lines represent means. (B) Summary
data showing percentages of CD62L-, CD69- and CD16-
expressing cells of either CCR7
+ or CCR7
2CD56
bright NK cells
or CD56
dimCD16
+ NK cells. Horizontal lines depict means. (C)
The percentage of cells displaying NKG2A and CD27 of CCR7
+
or CCR7
2CD56
bright NK cells or CD56
dimCD16
+ NK cells is
shown in HIV-seronegative individuals (n=4). (D) The frequen-
cies of cells expressing intracellular granzyme B and perforin of
CCR7
+ or CCR7
2CD56
bright NK cells or CD56
dimCD16
+ NK
cells are shown in uninfected control subjects (n=3). **, P,0.01;
***, P,0.001.
(EPS)
Figure S4 Functional alterations indicate a higher acti-
vation status of NK cells in untreated HIV-seropositive
individuals. (A) Sorted NK cells were stimulated with IL-12, IL-
15 and K562 cells and the percentages of cells expressing IFN-c
and TNF-a were measured in CD56
bright NK cells derived from
untreated HIV-positive and uninfected control donors. Horizontal
bars represent means. (B) The frequencies of Ki-67-expressing cells
in CCR7
+CD56
bright, total CD56
bright and CD56
dimCD16
+ NK
cells are shown. Untreated HIV-seropositive and uninfected
control donors were compared. Horizontal bars represent means.
(EPS)
Figure S5 Cytokine-treatment of CCR7
+CD56
bright cells
can induce NK cell differentiation. (A) Highly purified
CCR7
+CD56
bright NK cells were obtained from uninfected blood
donors by cell sorting. Numbers in representative flow cytometry
plots indicate frequencies of gated events. (B) Expression of CCR7
is shown at day 1, 3 and day 5 of cell culture. Numbers in corners
indicate the percentages of quadrants. Data is representative for
two independent experiments with similar results. (C) Expression
of granzyme B and perforin is shown at day 0, 3 and 5 of culturing
CCR7
+CD56
bright in medium or in the presence of cytokines.
Representative data of two independent experiments is shown.
(EPS)
Table S1 Demographic data of HIV-infected study
subjects. Data is shown for each HIV-seropositive study
participant.
(DOCX)
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